Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zellwerk is a German biotechnology company specializing in advanced bioprocessing solutions for cell culture and tissue engineering. Founded in 1997, the company is best known for its proprietary Z®RP (Zellwerk Rotating Processor) technology, a modular perfusion bioreactor system designed for the automated, GMP-compliant expansion of adherent mammalian cells. Zellwerk operates as both a technology provider and a CDMO, offering mass production services for immune cells—including natural killer (NK) cells and tumor-infiltrating lymphocytes (TILs)—as well as mesenchymal stem cells (MSCs) for regenerative medicine. Their innovative bioreactors create a tissue-like environment through a unique rotating bed design and laminar flow, aimed at enhancing the yield and purity of advanced therapy medicinal products (ATMPs).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zellwerk.